Patterns of Dose Escalation Amongst Patients with Ulcerative Colitis and Crohn's Disease Treated with Vedolizumab vs. Infliximab in the United States

被引：0
|
作者：
Khalid, Javaria Mona [1 ]
Raluy-Callado, Mireia [2 ]
Li, Qian [3 ]
Luo, Michelle [4 ]
Lasch, Karen [4 ]
机构：
[1] Takeda Dev Ctr Europe Ltd, London, England
[2] Evidera, London, England
[3] Evidera, Lexington, MA USA
[4] Takeda Pharmaceut USA Inc, Deerfield, IL USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2016年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
700
引用
收藏
页码：S316 / S317
页数：2
相关论文
共 50 条
  • [41] Early Failure of Infliximab in Patients with Ulcerative Colitis as Compared to Patients with Crohn's Disease
    Shah, Rushikesh
    Herrera, Henry
    Swaroop, Prabhakar
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S507 - S507
  • [42] Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
    Vijay Yajnik
    Nabeel Khan
    Marla Dubinsky
    Jeffrey Axler
    Alexandra James
    Brihad Abhyankar
    Karen Lasch
    Advances in Therapy, 2017, 34 : 542 - 559
  • [43] Outcomes after dose escalation of infliximab in Japanese patients with Crohn's disease
    Sako, M.
    Kawaguchi, T.
    Hirayama, A.
    Fukushi, G.
    Hayama, K.
    Fujiwara, T.
    Yoshimura, N.
    Takazoe, M.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S231 - S231
  • [44] Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
    Rosario, M.
    Dirks, N. L.
    Gastonguay, M. R.
    Fasanmade, A. A.
    Wyant, T.
    Parikh, A.
    Sandborn, W. J.
    Feagan, B. G.
    Reinisch, W.
    Fox, I.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (02) : 188 - 202
  • [45] The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 330 - 338
  • [46] Infliximab vs. Adalimumab for Crohn's disease
    Mulani, P.
    Chao, J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (10) : 1265 - 1266
  • [47] Population pharmacokinetics of subcutaneous vedolizumab in Crohn's disease and Ulcerative Colitis
    Vreman, N.
    Anjie, S., I
    Gecse, K. B.
    Lowenberg, M.
    D'Haens, G. R. A. M.
    Mathot, R. A. A.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1256 - I1257
  • [48] Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis
    Kaplan, G. G.
    Hur, C.
    Korzenik, J.
    Sands, B. E.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (11-12) : 1509 - 1520
  • [49] Indicators of Suboptimal Biologic Therapy in Patients With Ulcerative Colitis or Crohn's Disease in the United States
    Mody, Reema
    Patel, Haridarshan
    Rubin, David T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S824 - S824
  • [50] Clinical Characteristics of Patients With Crohn's Disease or Ulcerative Colitis Treated With Vedolizumab - A Real-World Data Analysis
    Liang, Huifang
    Manne, Sudhakar
    Shick, Jesse
    Yu, Shawn
    Fusco, Gregory
    Dolin, Paul
    GASTROENTEROLOGY, 2016, 150 (04) : S789 - S789
12345